Literature DB >> 25890630

Meta-analysis of comparison between self-expandable and balloon-expandable valves for patients having transcatheter aortic valve implantation.

Claudio Moretti1, Fabrizio D'Ascenzo1, Marco Mennuni2, Salma Taha3, Nedy Brambilla4, Freek Nijhoff5, Chiara Fraccaro6, Marco Barbanti7, Corrado Tamburino7, Giuseppe Tarantini6, Marco L Rossi2, Patrizia Presbitero2, Massimo Napodanno6, Pieter Stella5, Francesco Bedogni4, Pierluigi Omedè1, Federico Conrotto8, Antonio Montefusco1, Francesca Giordana1, Giuseppe Biondi Zoccai9, Piefrancesco Agostoni5, Maurizio D'Amico8, Mauro Rinaldi10, Sebastiano Marra8, Fiorenzo Gaita1.   

Abstract

Two different devices, 1 self-expanding and 1 balloon-expandable, have been developed for patients who underwent transcatheter aortic valve implantation with contrasting data about efficacy and safety. Pubmed, Medline, and Google Scholar were systematically searched for studies of these different devices, with data derived from randomized controlled trial or registries with multivariate analysis. All-cause death at 30 days and at follow-up were the primary end points, whereas postprocedural moderate or severe aortic regurgitation (AR), stroke, major vascular complications, bleedings, and pacemaker implantation the secondary ones. Six studies with 957 self-expanding and 947 balloon-expandable valves were included: 1 randomized controlled trial and 5 observational studies. At 30 days follow-up, rates of death did not differ between self-expanding and balloon-expandable valves (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.47 to 1.17), whereas balloon expandable reduced rates of moderate or severe AR (OR 0.51, 95% CI 0.27 to 0.99) and of pacemaker implantation (OR 0.28, 95% CI 0.17 to 0.47). After a follow-up of 360 days (300 to 390), rates of all-cause death did not differ between the 2 groups. In conclusion, risks of moderate or severe AR and pacemaker implantation were lower with the balloon-expandable devices without an impact on 30 days and midterm mortality.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25890630     DOI: 10.1016/j.amjcard.2015.03.015

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Transcatheter aortic valve implantation: a revolution in the therapy of elderly and high-risk patients with severe aortic stenosis.

Authors:  Teoman Kilic; Irem Yilmaz
Journal:  J Geriatr Cardiol       Date:  2017-03       Impact factor: 3.327

2.  Safety and efficacy of self-expandable Evolut R vs. balloon-expandable Sapien 3 valves for transcatheter aortic valve implantation: A systematic review and meta-analysis.

Authors:  Chenglin He; Lang Xiao; Junli Liu
Journal:  Exp Ther Med       Date:  2019-09-12       Impact factor: 2.447

Review 3.  Updates on transcatheter aortic valve replacement: Techniques, complications, outcome, and prognosis.

Authors:  Jarrah Alfadhli; Mohammed Jeraq; Vikas Singh; Claudia Martinez
Journal:  J Saudi Heart Assoc       Date:  2018-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.